Ustekinumab market?

Here’s a concise market snapshot for ustekinumab (Stelara):

- What it is: A monoclonal antibody that targets the p40 subunit shared by IL-12 and IL-23. It’s given by subcutaneous injection.

- Approved indications (US/EU and major markets):
- Plaque psoriasis
- Psoriatic arthritis
- Crohn’s disease
- Ulcerative colitis
(Indication approvals have expanded over the years; UC approval came later than the others.)

- Market position and sales
- Ustekinumab is a high‑value, multi‑indication biologic and one of Janssen’s top-selling products.
- Global net sales have been in the multi‑billion range annually in recent years (roughly in the high single digits to low double digits in billions, e.g., around $9–11B per year in the past few years). Growth has been supported by expanding indications and long dosing intervals, but faces price and payer pressures.

- Key market dynamics
- Drivers: longer dosing interval after induction (every 12 weeks for some indications), strong efficacy across inflammatory conditions, and ongoing expansion of approved indications.
- Competition: strong competition from other IL‑23 inhibitors (e.g., guselkumab, risankizumab) and from biologics targeting TNF or IL‑17 pathways (e.g., secukinumab, ixekizumab, adalimumab, infliximab). Also, small‑molecule JAK inhibitors (e.g., tofacitinib, upadacitinib) as alternatives in some indications.
- Regulation and reimbursement: pricing and payer access are important market forces; pharmacovigilance and long‑term safety profiles influence uptake.
- Biosimilars: US approvals for ustekinumab biosimilars have been limited; EU and other markets have seen biosimilar introductions with varying uptake (if you need region-specific detail, I can pull the latest data).

- Market by region (high level)
- United States and Europe are the largest markets.
- Asia-Pacific is growing, with increasing access and new prescriber adoption.

If you want, I can tailor this to a specific region (US, EU, APAC) or provide a current year/future forecast (e.g., 2024–2029) with latest market research figures. What region or time horizon are you interested in?